Animal Health

ELIAS Animal Health, an affiliate of TVAX Biomedical, is focused on adapting TVAX Immunotherapy® for applications in the veterinary sector with an initial focus on osteosarcoma in dogs, a deadly form of bone cancer.

Cancer is a leading cause of death for dogs and the #1 health concern for U.S. dog owners. Market research indicates more than 6 million dogs and nearly 6 million cats are diagnosed with cancer annually, yet there are limited treatment options available for veterinarians to use.

ELIAS Animal Health, LLC has licensed the worldwide rights to TVAX Immunotherapy technology for non-human animals. The USDA Center for Veterinary Biologics has authorized the company  to market this novel immunotherapy to veterinarians for treatment of cancer in dogs, cats and horses.

ELIAS is conducting clinical trials in key canine cancers, to determine the safety and efficacy of TVAX Immunotherapy as a treatment across a broad range of canine cancer types under the regulatory requirements of the USDA Center for Veterinary Biologics.

ELIAS will market this treatment in the veterinary sector under the name ELIAS Cancer Immunotherapy (ECI®).For the latest updates, please visit the ELIAS Animal Health news page.